Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial, but raises safety concerns
(CNN) – The investigational drug lecanemab shows “potential” as a treatment for Alzheimer’s disease, according to new Phase 3 trial results, but the results raise safety concerns because of its association with certain events serious adverse reactions. Lecanemab has become one of the first experimental dementia drugs to appear to slow the progression of cognitive …
